Latest Thesis
Aurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilution
Aurora is trying to leave the worst cannabis-stock habits behind: Q3 FY2026 medical cannabis revenue set a record, management is exiting weaker Canadian consumer lanes, and the balance sheet has cash. The catch is that IFRS losses, Bevo restructuring, internal-control weaknesses, and an open ATM keep the turnaround on probation.
Financials and workspace tools are for paid members.
Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.
Recent Reports
Compact report index for this company.
ReportTypeUpdatedReadActions
Aurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionAurora is trying to leave the worst cannabis-stock habits behind: Q3 FY2026 medical cannabis revenue set a record, management is exiting weaker Canadian consumer lanes, and the balance sheet has cash. The catch is that IFRS losses, Bevo restructuring, internal-control weaknesses, and an open ATM keep the turnaround on probation.NASDAQMay 13, 2026Research reportReadSlides